

This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

Notices:

- License integration enhancement has been postponed. The launch was not successful
- We are working with Appriss on being able to issue automatic compliance notifications to providers who directly dispense, letting them know if they miss a day of reporting.
- The RFP for the PDMP contract has been issued; we are in the process of evaluating the proposals and anticipate selecting a vendor by the end of the year.
- The PDMP received two grants: The State Opioid Response (SOR) grant and a partial award of the Bureau of Justice Assistance (BJA) grant.
- We will be focusing on training opportunities in the coming months

Registration

Portal

Number of licensed Dentists: 841 (821 licensees in August 2020)

Number of Dentists with DEA registrations: 716

Number of PDMP Dental registrations: 374

Compliance rate (DEA and PDMP registrations): 52%

AWARxE (PDMP)

Number registered with the PDMP: 672 (669 registered in August 2020)

Compliance rate (DEA and AWARxE): 94%

Use

Review compliance from July – October 2020: 5.62% (623 dispensations; 35 searched)

MME Use (July 2020 – October 2020)

Number of patients treated with over 90 MME: 39

Number of patients treated with over 120 MME: 9

Number of patients treated with dangerous combinations (benzodiazepines and opioids): 251

Delinquent Reporters

Providers who directly dispense are required to report daily. We are currently gathering this information on the renewal applications.

Recommendations

- Encourage increased reviewing, including the use of delegates
- Provide guidance to licensees on prescribing practices related to the use of dangerous combinations
- Providers should be notified they are not able to prescribe until their registration in AWARxE has been approved
- Encourage licensees to verify their user roles and specialties in AWARxE to improve the accuracy of reporting.
- Improve communication to licensees, post-licensure, to give better instructions on how to comply with PDMP statutes and regulations

**PDMP Overview
 Registration**




Figure 1A. Physician includes those registered as Physician, Podiatrist, and Medical Residents with Prescriptive Authority. *Other includes IHS, VA, and military prescribers and dispensers, admin, coroners, and out-of-state pharmacists.




Figure 1B. This figure may be underrepresented as there are licensed prescribers inclusive in federal user role categories (IHS Prescriber, VA Prescriber, and Military Prescribers).

Alaska Prescription Drug Monitoring Program
Summary Prepared for the Board of Dental Examiners
December 2020



MME Use

June 2020 – October 2020

The CDC recommends that primary care clinicians should reassess evidence of the benefits and risks to the individual when increasing dosage to greater or equal to 50 MME/day and avoid increasing to greater or equal to 90 MME/day when possible due to an increased risk of complications. The CDC also recommends avoiding concurrent benzodiazepine and opioid prescriptions, given the high risk of adverse drug-drug interactions, specifically respiratory depression and death.

CDC checklist for prescribing opioids -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDC_06.2018.pdf

CDC guidelines for prescribing opioids for chronic pain -

https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDCPain_2018.10.pdf

Provider Type	# Providers Prescribing at Least Once	# Providers Who Reviewed 0 Patients	# Providers Prescribing >90MME	# Providers Prescribing >120MME	Dangerous Combo	
					Benzo Opioid	Benzo Opioid Carisoprodol
NUR	499	22% (112)	12% (59)	7% (37)	25% (124)	1% (7)
DEN	311	60% (187)	5% (17)	1% (4)	26% (80)	0
MED	1354	31% (421)	20% (273)	12% (165)	32% (438)	2.6% (35)
PA	294	24% (72)	17% (49)	12% (35)	26% (77)	2% (7)
VET	171	76% (130)	2% (4)	2% (4)	6% (10)	0
OPT	2	100% (2)	0	0	0	0